Essai clinique
Récupéré
Publication
clinicaltrials.gov
Hugo W. Moser Research Institute at Kennedy Krieger, Inc.
(2013).
Rapalogues for Autism Phenotype in TSC: A Feasibility Study.
ClinicalTrials.gov.
Hugo W. Moser Research Institute at Kennedy Krieger, Inc..
- Date de publication
-
2013
- Identifiant
-
NCT01929642
- Auteurs
-
Hugo W. Moser Research Institute at Kennedy Krieger, Inc.
- Source
- ClinicalTrials.gov
- Type de référence
- clinical_trial
- Éditeur
- Hugo W. Moser Research Institute at Kennedy Krieger, Inc.
- Source de métadonnées
- clinicaltrials.gov
Résumé
The purpose of this study is to assess the feasibility and safety of administering rapalogues, sirolimus or everolimus, in participants with Tuberous Sclerosis Complex (TSC) and self-injury and to measure cognitive and behavioral changes, including reduction in autistic symptoms, self-injurious and aggressive behaviors, as well as improvements in cognition across multiple domains of cognitive function.